Development of PLX-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation Syndrome
Award Notice Posted
- Solicitation number
- NIAID-BAA-75N93021R00019
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Pluri Biotech LTD
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93023C00012 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Haifa Israel
Notice details come from SAM.gov. Updated .
About this opportunity
PLURI BIOTECH LTD has been awarded a single contract valued at $4,175,466 by the National Institute of Allergy and Infectious Diseases within the Department of Health and Human Services to develop PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome over the period of performance. The contract will support PLURI BIOTECH LTD's development of this cell therapy to treat the hematopoietic form of acute radiation syndrome.
Notice text
Awarded contract 75N93023C00012 to PLURI BIOTECH LTD for 4175466.00 on 2023-07-01.
Notice history
10 of 12 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity